… The use of ACEI’s in heart failure is well established and as proven to reduce … cardiovascular
risk with heart failure and left ventricular dysfunction candesartan, losartan and valsartan is …

… receptor antagonist (valsartan), or combined treatment. Vehicle… The LVMI model is a well
described model of heart failure … Infarct size tion of cardiac tissue (0.5–1.2 g) was used to purify …

SciELO - Brasil - Effect of candesartan treatment on echocardiographic indices of cardiac
remodeling in post-myocardial infarction patients Effect of candesartan treatment on …

… and morbidity in patients post-myocardial infarction as well as in chronic heart failure and …
detect a 15% reduction in mortality rate with either use of valsartan compared with captopril. …

… In addition, the VALIANT trial showed noninferiority for valsartan, an angiotensin receptor
blocker, … In this study, the use of TZD therapy was associated with a 17% increased risk of …

… and valsartan, alone and in combination, in patients with MI … heart disease events was
demonstrated with statin use. In the … ) of 4444 patients with ischemic heart disease followed up for …

… We used the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial to characterize …
on 1-year mortality and major cardiovascular events in patients with heart failure and/or left …

… The results of our study could be limited by the dosages we used both for lisinopril and
valsartan. When this study was designed the recommended doses of lisinopril and …

… We think that the possible benefits of sacubitril/valsartan use in daily practice as well as
reduction in mortality and hospitalisation cannot be ignored in HF management. …

… disease and left ventricular hypertrophy. Furthermore, the drug is evaluated for its efficacy in
heart failure and patients post-myocardial infarction. … Intravenous application of valsartan to …